FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average I	hurden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SULLIVAN LOUIS W					2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [EBS]										ionship o all applio Directo	•		son(s) to Iss 10% Ov	
(Last) 2273 RE	(Fi SEARCH I	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/20/2010									Officer below)	(give title		Other (sbelow)	specify	
(Street) ROCKV (City)		tate)	20850 (Zip)		-	4. If Amendment, Date of Original Filed (Month/Day/Year)						Lir	Individual or Joint/Group Filing (Check Applicable le) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
		Tab	le I - Noi	n-Deriv	/ative	Se	curitie	s Ac	quired	, Dis	posed o	of, or Be	neficia	lly C)wned				
D		2. Trans Date (Month/	Day/Year) i		2A. Deemed Execution Date, if any (Month/Day/Year)		, Transaction Disposed (Code (Instr. 5)		ities Acquii d Of (D) (In		nd Securition Benefici Owned I		s ally following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) o	Price	1	Reported Transact (Instr. 3 a	tion(s)			(Instr. 4)
Common Stock ⁽¹⁾ 05/20/				0/2010	2010		A		3,600	500 ⁽²⁾ A			3,600			D			
		Т	able II -									, or Ben ble sec		y Ow	vned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year		4. Transaction Code (Instr. 8)		n of E		Expiratio	6. Date Exercisable Expiration Date Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		Deri Sec	s. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares	per					
Director Stock Option (right to	\$16.13	05/20/2010		Ì	A		7,200		(3)	0	05/19/2020	Common Stock	7,200		\$0	7,200		D	

Explanation of Responses:

- 1. Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan.
- 2. These restricted stock units vest in three equal annual installments beginning on the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
- 3. The option will vest in three equal installments on May 21, 2011, May 21, 2012 and May 21, 2013 or, if the Company's Annual Meeting of Stockholders occurs prior to such date for any year, on the day prior to such year's Annual Meeting of Stockholders.

Remarks:

/s/R. Don Elsey, attorney-infact 05/24/2010

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.